194 related articles for article (PubMed ID: 36741213)
1. Role of Luspatercept in the Management of Lower-Risk Myelodysplastic Syndromes.
Tinsley-Vance SM; Davis M; Ajayi O
J Adv Pract Oncol; 2023 Jan; 14(1):82-87. PubMed ID: 36741213
[TBL] [Abstract][Full Text] [Related]
2. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
3. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux P; Platzbecker U; Mufti GJ; Garcia-Manero G; Buckstein R; Santini V; Díez-Campelo M; Finelli C; Cazzola M; Ilhan O; Sekeres MA; Falantes JF; Arrizabalaga B; Salvi F; Giai V; Vyas P; Bowen D; Selleslag D; DeZern AE; Jurcic JG; Germing U; Götze KS; Quesnel B; Beyne-Rauzy O; Cluzeau T; Voso MT; Mazure D; Vellenga E; Greenberg PL; Hellström-Lindberg E; Zeidan AM; Adès L; Verma A; Savona MR; Laadem A; Benzohra A; Zhang J; Rampersad A; Dunshee DR; Linde PG; Sherman ML; Komrokji RS; List AF
N Engl J Med; 2020 Jan; 382(2):140-151. PubMed ID: 31914241
[TBL] [Abstract][Full Text] [Related]
4. Novel agents for myelodysplastic syndromes.
Xu K; Hansen E
J Oncol Pharm Pract; 2021 Dec; 27(8):1982-1992. PubMed ID: 34558354
[TBL] [Abstract][Full Text] [Related]
5. The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia.
Delgado J; Voltz C; Stain M; Balkowiec-Iskra E; Mueller B; Wernsperger J; Malinowska I; Gisselbrecht C; Enzmann H; Pignatti F
Hemasphere; 2021 Aug; 5(8):e616. PubMed ID: 34291195
[TBL] [Abstract][Full Text] [Related]
6. Development of luspatercept to treat ineffective erythropoiesis.
Kubasch AS; Fenaux P; Platzbecker U
Blood Adv; 2021 Mar; 5(5):1565-1575. PubMed ID: 33687432
[TBL] [Abstract][Full Text] [Related]
7. Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial.
Oliva EN; Platzbecker U; Garcia-Manero G; Mufti GJ; Santini V; Sekeres MA; Komrokji RS; Shetty JK; Tang D; Guo S; Liao W; Zhang G; Ha X; Ito R; Lord-Bessen J; Backstrom JT; Fenaux P
J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011768
[TBL] [Abstract][Full Text] [Related]
8. Luspatercept in combination with recombinant erythropoietin in patients with myelodysplastic syndrome with ring sideroblasts: Stimulating early and late-stage erythropoiesis.
Fattizzo B; Versino F; Bortolotti M; Rizzo L; Riva M; Barcellini W
Eur J Haematol; 2023 May; 110(5):571-574. PubMed ID: 36727250
[TBL] [Abstract][Full Text] [Related]
9. Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.
Germing U; Fenaux P; Platzbecker U; Buckstein R; Santini V; Díez-Campelo M; Yucel A; Tang D; Fabre S; Zhang G; Zoffoli R; Ha X; Miteva D; Hughes C; Komrokji RS; Zeidan AM; Garcia-Manero G
Ann Hematol; 2023 Feb; 102(2):311-321. PubMed ID: 36635381
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.
Platzbecker U; Götze KS; Kiewe P; Germing U; Mayer K; Radsak M; Wolff T; Chromik J; Sockel K; Oelschlägel U; Haase D; Illmer T; Al-Ali HK; Silling G; Reynolds JG; Zhang X; Attie KM; Shetty JK; Giagounidis A
J Clin Oncol; 2022 Nov; 40(33):3800-3807. PubMed ID: 35998303
[No Abstract] [Full Text] [Related]
11. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
Molica M; Rossi M
Expert Opin Biol Ther; 2024 Apr; 24(4):233-241. PubMed ID: 38555469
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndromes with ring sideroblasts.
Bruzzese A; Vigna E; Martino EA; Mendicino F; Lucia E; Olivito V; Bova C; Barbato A; Filippelli G; Capodanno I; Neri A; Morabito F; Gentile M
Hematol Oncol; 2023 Oct; 41(4):612-620. PubMed ID: 36794650
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
Patnaik MM; Tefferi A
Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
[TBL] [Abstract][Full Text] [Related]
14. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management".
Patnaik MM; Tefferi A
Am J Hematol; 2019 Apr; 94(4):475-488. PubMed ID: 30618061
[TBL] [Abstract][Full Text] [Related]
15. Luspatercept in Myelodysplastic Syndromes: Who and When?
Komrokji RS
Hematol Oncol Clin North Am; 2020 Apr; 34(2):393-400. PubMed ID: 32089218
[TBL] [Abstract][Full Text] [Related]
16. Treatment of refractory or relapsed myelodysplastic neoplasms with luspatercept: a multicenter Chinese study.
Zhang Z; Hu Q; Tang X; Zhang M; Jia J; Shi H; Ding X; Yang C; Chen M; Han B
Ann Hematol; 2023 Nov; 102(11):3039-3047. PubMed ID: 37682325
[TBL] [Abstract][Full Text] [Related]
17. Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
Volpe VO; Komrokji RS
Ther Adv Hematol; 2021; 12():2040620720986641. PubMed ID: 33505645
[TBL] [Abstract][Full Text] [Related]
18. Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept.
Delanghe S; Nguyen TQ; Mazure D; Dendooven A; Speeckaert MM
Diagnostics (Basel); 2022 Dec; 13(1):. PubMed ID: 36611303
[TBL] [Abstract][Full Text] [Related]
19. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts.
Schulz F; Nachtkamp K; Kasprzak A; Gattermann N; Haas R; Germing U
Expert Rev Hematol; 2021 Jun; 14(6):509-516. PubMed ID: 34161752
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.
Battaglia MR; Cannova J; Madero-Marroquin R; Patel AA
Curr Treat Options Oncol; 2024 May; ():. PubMed ID: 38814537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
